Doggett Announces Ways & Means Medicare Drug-Pricing Hearing
Published by Inside Health Policy
The House Ways & Means health subcommittee will hold a hearing on promoting competition to lower prescription drug prices in Medicare on March 7, chair Rep. Lloyd Doggett (D-TX) announced Thursday (Feb. 28). The committee is the latest to join the congressional dogpile of hearings on the issue, including a two-day Senate Special Committee on Aging hearing, of which the second session will be held on the same day.
Allowing Medicare to directly negotiate drug prices was a topic of heated discussion during the full Ways & Means drug-pricing hearing on Feb. 12. Overall committee ranking Republican Rep. Kevin Brady (TX) came out staunchly against the proposal. Doggett promoted his price-negotiation bill that includes compulsory licensing as an enforcement tool, but also maintained his stance that he is open to other negotiation models.
Doggett’s price-negotiation bill is the highest-profile proposal thus far with more than 100 House co-sponsors. It would allow HHS to negotiate prices for all Medicare Part D drugs, though Republicans largely inquired about how to address the costs of expensive, single-source drugs. — Rachel Cohrs (rcohrs@iwpnews.com)
Click here to see the original article on the Inside Health Policy website.
Recent Posts
-
NCPA Advocates for Medicare Drug Price Negotiation Program Overhaul Due to Pharmacy Cash Flow
With its initial rollout beginning in 2026, the Medicare Drug Price Negotiation Program has caused significant strain on the cash flow of independent pharmacies.
The National Community Pharmacists Association (NCPA) is sounding the alarm over the federal government’s implementation of the Medicare Drug Price Negotiation Program (MDPNP) after a recent survey of its members revealed significant financial distress, according to a news release.
-
Pharmacies To Face Low Cash Flow For MFP Drugs Until Fixes Emerge
A bill introduced last year aiming to ensure long-term care (LTC) pharmacies can continue to supply and dispense Medicare Part D drugs despite lower prices resulting from the price negotiation program will need to be tweaked to ensure the intended relief is retroactive, according to Alan Rosenbloom, executive director of the Senior Care Pharmacy Coalition (SCPC).
-
SCPC Applauds Inclusion of PBM Reform in Recent Spending Package Approved by U.S. House & Senate
The Senior Care Pharmacy Coalition (SCPC), the leading voice for the nation’s long-term care (LTC) pharmacy community, released the following statement about the passage of PBM reform: “SCPC applauds the passage of bipartisan pharmacy benefit manager (PBM) reform legislation by both the U.S. House and Senate, marking a significant step toward greater transparency, accountability, and fairness in the prescription drug marketplace. These […]
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.